Arcus Biosciences Long Term Debt

Arcus Biosciences (RCUS) currently reports a long-term debt of $100M as of March 2026. That compares with $48M in the prior-year period — up 108.3% year over year. Use the charts on this page to explore Arcus Biosciences's long-term debt history and peer comparisons.

Arcus Biosciences's long-term debt increased from $48M to $100M — a 108.3% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Arcus Biosciences reported $100M in long-term debt as of March 2026. That compares with $48M in the prior-year period — up 108.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $100M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Arcus Biosciences, and consider following RCUS for alerts when major investors trade the stock.

Arcus Biosciences is classified in the Healthcare sector. On long-term debt, it currently shows $100M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RCUS with unrelated industries.